Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock

Authors

  • Muhammad Imam Faculty of Medicine, Padjadjaran University, Bandung City, West Java, Indonesia
  • Sebastian Faculty of Medicine, Padjadjaran University, Bandung City, West Java, Indonesia

Keywords:

Selepressin, Placebo, Ventilator, Vasopressor, Septic Shock

Abstract

Background: The exploration of the effects of selepressin versus placebo in patients experiencing septic shock is an emerging area of interest in critical care medicine. The literature surrounding this topic reveals a complex interplay between vasopressor use, patient outcomes, and potential complications associated with septic shock management. Literature Review: The literature surrounding the effects of selepressin versus placebo in patients with septic shock reveals a nuanced understanding of its potential benefits and limitations in critical care settings. The introduction highlights the significance of vasopressor management in septic shock and sets the stage for a detailed examination of selepressin's role, particularly its impact on ventilator- and vasopressor-free days. Conclusion: In conclusion, the literature suggests that selepressin presents a promising alternative to traditional vasopressors in the management of septic shock, particularly in its ability to maintain hemodynamic stability and potentially reduce the duration of mechanical ventilation. However, the variability in trial outcomes and the lack of significant differences in primary endpoints underscore the need for further research to clarify the role of selepressin in clinical practice. Continued exploration of its effects on secondary outcomes may provide valuable insights into optimizing treatment strategies for patients with septic shock.

References

A. Russell, J., Vincent, J. L., Louise Kjølbye, A., Olsson, H., Blemings, A., Spapen, H., Carl, P., Laterre, P. F., & Grundemar, L., 2017. Selepressin, a novel selective vasopressin V(1A) agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. ncbi.nlm.nih.gov

Demiselle, J., Fage, N., Radermacher, P., & Asfar, P., 2020. Vasopressin and its analogues in shock states: a review. ncbi.nlm.nih.gov

Jozwiak, M., Geri, G., Laghlam, D., Boussion, K., Dolladille, C., & S. Nguyen, L., 2022. Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review. ncbi.nlm.nih.gov

Downloads

Published

2024-07-01

How to Cite

Muhammad Imam, Muhammad Imam, and Sebastian Sebastian. 2024. “Effect of Selepressin Vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock”. The International Journal of Medical Science and Health Research 2 (7): 22-29. https://doi.org/10.70070/7036j221.